TCEAL8 Inhibitors
In the context of transcriptional regulation, TCEAL8 inhibitors target various pathways to exert their functional repression. Compounds that inhibit kinases in the MAPK/ERK and PI3K/AKT pathways play a significant role in this context, as they decrease the activation of transcription factors that may be crucial for the transcriptional events TCEAL8 is involved in. Inhibition of the mTOR pathway can also lead to a general reduction in protein synthesis, which includes proteins that could regulate or be regulated by TCEAL8, thus diminishing its activity indirectly. Furthermore, JNK inhibitors can alter transcriptional complexity, potentially affecting the transcriptional processes that TCEAL8 may facilitate. Inhibition of cell cycle regulatory kinases could also affect TCEAL8 function by disrupting the transcriptional programs that are dependent on the cell cycle, thereby indirectly influencing TCEAL8's role in transcriptional regulation.
On a more epigenetic level, inhibitors like histone deacetylase inhibitors and DNA methyltransferase inhibitors can change the chromatin landscape and gene expression patterns. By modifying chromatin accessibility and DNA methylation status, these compounds can indirectly affect the activity of TCEAL8 by altering the transcriptional environment in which it operates. Histone methyltransferase inhibitors further contribute to such changes by affecting histone methylation, thus potentially altering the transcriptional regulation of genes that interact with TCEAL8.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which is a kinase involved in the MAPK/ERK pathway. TCEAL8, being part of the transcriptional machinery, may see reduced activity due to decreased transcription factor activation as a result of inhibited MAPK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that reduces AKT phosphorylation, leading to altered transcriptional activity. Since TCEAL8 functions in transcription, its activity could be diminished by the reduced transcription factor activity downstream of PI3K/AKT. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAPK, affecting the cellular response to stress and inflammatory cytokines. Inhibition of p38 MAPK may lead to decreased regulation of transcription factors that interact with TCEAL8. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that can lead to a decrease in AKT activity and subsequent transcription factor inactivity. The functional activity of TCEAL8 could be reduced due to less active transcriptional events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that affects protein synthesis by acting on the mTORC1 complex. TCEAL8 activity could decline due to a general downregulation of protein synthesis, including proteins that interact with or regulate TCEAL8. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which modulates transcription factors. Reduced JNK activity can lead to decreased transcriptional complexity, potentially affecting TCEAL8-dependent transcription processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, leading to reduced ERK pathway signaling. This can result in decreased transcription factor activity that would otherwise engage with TCEAL8 in transcriptional regulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that changes the chromatin structure and affects gene expression. This may indirectly affect TCEAL8 by altering the availability of transcriptional targets and regulators. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that leads to hypomethylation of DNA and altered gene expression. It may affect TCEAL8 activity by changing the expression patterns of genes that regulate or are regulated by TCEAL8. | ||||||
Apicidin | 183506-66-3 | sc-202061 sc-202061A | 1 mg 5 mg | $110.00 $343.00 | 9 | |
A histone deacetylase inhibitor that could alter chromatin accessibility and potentially decrease TCEAL8 activity by modifying the transcriptional landscape. | ||||||